BioPulse International, Inc. has acquired a new and improved method of creating dendritic cell cancer vaccines. “Antigens associated with cancerous tumours are not normally recognized by the immune system. With dendritic cell therapy, we’re teaching the dendritic cells to recognize the cancer antigens,” explains Dr. Robert Morrow, Director of Clinical Research for BioPulse. If the Read more about Biopulse Acquires Cancer Vaccine[…]